Promising new combo therapy targets aggressive lung cancer

NCT ID NCT05142696

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 29 times

Summary

This study tests a new treatment for people with extensive stage small cell lung cancer, a fast-growing cancer. It combines a radioactive drug with standard chemotherapy and immunotherapy to see if it works better than standard care alone. About 24 adults who have not had prior treatment will take part to find a safe dose and check if it helps them live longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Advent Health Cancer Institute

Orlando, Florida, 32804, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Georgetown University Lombardi Cancer Center

Washington D.C., District of Columbia, 20007 2197, United States
Hackensack Meridian Health

Edison, New Jersey, 88837, United States
Novartis Investigative Site

Innsbruck, Tyrol, 6020, Austria
Novartis Investigative Site

Linz, Upper Austria, A 4020, Austria
Novartis Investigative Site

Vienna, A-1090, Austria
Novartis Investigative Site

Montreal, Quebec, H3T 1E2, Canada
Novartis Investigative Site

Beijing, 100036, China
Novartis Investigative Site

Shanghai, 200032, China
Novartis Investigative Site

Olomouc, 779 00, Czechia
Novartis Investigative Site

Bron, 69677, France
Novartis Investigative Site

Lille, 59000, France
Novartis Investigative Site

Marseille, 13885, France
Novartis Investigative Site

Montpellier, 34298, France
Novartis Investigative Site

Nantes, 44093, France
Novartis Investigative Site

Villejuif, 94800, France
Novartis Investigative Site

Essen, 45147, Germany
Novartis Investigative Site

Hong Kong, 999077, Hong Kong
Novartis Investigative Site

Beersheba, 8457108, Israel
Novartis Investigative Site

Haifa, 3109601, Israel
Novartis Investigative Site

Ramat Gan, 5265601, Israel
Novartis Investigative Site

Tel Aviv, 6423906, Israel
Novartis Investigative Site

Milan, MI, 20133, Italy
Novartis Investigative Site

Naples, 80131, Italy
Novartis Investigative Site

Amersfoort, 3813, Netherlands
Novartis Investigative Site

Singapore, 168583, Singapore
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Barcelona, Catalonia, 08035, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Madrid, 28040, Spain
Novartis Investigative Site

Madrid, 28041, Spain
Novartis Investigative Site

Málaga, 29010, Spain
Novartis Investigative Site

Taoyuan, 33305, Taiwan
Novartis Investigative Site

Guildford, Surrey, GU2 7XX, United Kingdom
St. Louis University

St Louis, Missouri, 63104, United States
University Cancer and Blood Center LLC

Athens, Georgia, 30607, United States
University Hospitals Of Cleveland

Cleveland, Ohio, 44106, United States
University of Kentucky

Lexington, Kentucky, 40536, United States
Vanderbilt University Medical Ctr

Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER EXTENSIVE-STAGE SMALL-CELL LUNG CANCER